The Current Position:Home > News Center
News Center
Innovative Anti-HIV Drug ACC007 Received CFDA Approval for Clinical Trials
2017-03-28 Source:江蘇艾迪藥業有限公司
       Clinical trial of ACC007, an innovative anti-HIV drug has been officially approved by China Food and Drug Administration (CFDA) on March 10th , 2017. ACC007 which is a kind of non-nucleoside reverse transcriptase inhibitors, is the second innovative drug in Aidea’s pipeline with intellectual property rights
Jiangsu Aidea Pharmaceutical Co., Ltd
Email:[email protected]
Address:No.2 Liuzhuang Road, Hanjiang District, Yangzhou
版權歸 ? "Jiangsu Aidea Pharmaceutical Co., Ltd所有 蘇ICP備14046468號 Powered by vancheer